Table 1.
Baseline characteristics of enrolled patients at initiation of regorafenib
| Variables | Overall (N = 122) |
|---|---|
| Age (years-old) | 65.7 (IQR 60.8-73.5) |
| Male gender | 103 (84.4) |
| Etiology | |
| HBV/HCV/others | 59/40/23 (48.4/32.8/18.8) |
| Child-Pugh A/B | 116/6 (95.1/4.9) |
| ALBI grade I/II/III | 59/62/1 (48.4/50.8/0.8) |
| BCLC stage B/C | 33/89 (27.0/73.0) |
| Macrovascular invasion | 40 (32.8) |
| Extra-hepatic metastasis | 63 (51.6) |
| AFP ≥ 400 ng/ml | 40 (32.8) |
| Prior lines of systemic therapy 0/1/≥ 2 | 0/97/25 (0/79.5/20.5) |
| Combination therapy | 31 (25.4) |
| Loco-regional therapy | 21 (17.2) |
| Immune checkpoint inhibitors | 10 (8.2) |
| Systemic chemotherapy | 3 (2.5) |
| Duration of therapy (months) | 4.1 (IQR 2.6-8.0) |
| Follow-up duration since therapy start (months) | 7.5 (IQR 4.2-13.7) |
Abbreviations: AFP, alpha-fetoprotein; ALBI, albumin-bilirubin index; BCLC, Barcelona Clinic Liver Cancer.